The Solid-Gold Wonder Drug.

The article discusses a hepatitis C drug with few side effects developed by Michael Sofia and colleagues, formerly at Pharmassett, which was purchased by biotechnology company Gilead, and approved by the U.S. Food and Drug Administration (FDA). An overview of the drug, which is comprised of an RNA polymerase inhibitor, called sofosbuvir, plus the antiviral ribavirin, the standard treatment of hepatitis C, which includes interferon plus ribavirin, and sofosbuvir's cost, are discussed.